A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- September 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Collaborative Neuroscience Research, LLC · Los Alamitos, CA
Florida · 2
- Research Centers of America ( Hollywood ) · Hollywood, FL
- Innovative Clinical Research, Inc. · Miami Lakes, FL
Georgia · 2
- Atlanta Center for Medical Research · Atlanta, GA
- CenExel iResearch, LLC · Decatur, GA
Illinois · 1
- Uptown Research Institute · Chicago, IL
New Jersey · 1
- Hassman Research Institute Marlton Site · Marlton, NJ
Texas · 1
- Community Clinical Research · Austin, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.